Association between gastrointestinal events and osteoporosis treatment initiation in women diagnosed with osteoporosis in France: a retrospective analysis

[1] Hernlund E(2013)Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos 8 136-400

[2] Svedbom A(2009)Prevalence and features of osteoporosis in the French general population: the Instant study Joint Bone Spine 76 394-46

[3] Ivergard M(2012)Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model Arch Osteoporos 7 237-10

[4] Compston J(2011)Management of osteoporosis and associated quality of life in post menopausal women BMC Musculoskelet Disord 12 7-21

[5] Cooper C(2013)Fear of falling, fracture history, and comorbidities are associated with health-related quality of life among European and US women with osteoporosis in a large international study Osteoporos Int 24 3001-66

[6] Stenmark J(2011)Impact of osteoporosis and vertebral fractures on quality-of-life. a population-based study in Valencia, Spain (The FRAVO Study) Health Qual Life Outcomes 9 20-13

[7] McCloskey EV(2009)Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women JAMA 301 513-14

[8] Jonsson B(2014)Mortality after hip fracture in austria 2008–2011 Calcif Tissue Int 95 257-84

[9] Kanis JA(2012)2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis Joint Bone Spine 79 304-7

[10] Lespessailles E(2007)Characterisation of patients with postmenopausal osteoporosis in French primary healthcare Drugs Aging 24 603-83

[1] Hernlund E(2013)Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos 8 136-400

[2] Svedbom A(2009)Prevalence and features of osteoporosis in the French general population: the Instant study Joint Bone Spine 76 394-46

[3] Ivergard M(2012)Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model Arch Osteoporos 7 237-10

[4] Compston J(2011)Management of osteoporosis and associated quality of life in post menopausal women BMC Musculoskelet Disord 12 7-21

[5] Cooper C(2013)Fear of falling, fracture history, and comorbidities are associated with health-related quality of life among European and US women with osteoporosis in a large international study Osteoporos Int 24 3001-66

[6] Stenmark J(2011)Impact of osteoporosis and vertebral fractures on quality-of-life. a population-based study in Valencia, Spain (The FRAVO Study) Health Qual Life Outcomes 9 20-13

[7] McCloskey EV(2009)Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women JAMA 301 513-14

[8] Jonsson B(2014)Mortality after hip fracture in austria 2008–2011 Calcif Tissue Int 95 257-84

[9] Kanis JA(2012)2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis Joint Bone Spine 79 304-7

[10] Lespessailles E(2007)Characterisation of patients with postmenopausal osteoporosis in French primary healthcare Drugs Aging 24 603-83